Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 15/20 | 0.39 |
| ▸ | HTR2C | P28335 | 14/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601778 | 0.80 | HTR2B (0.40) | NOTUMHTR2BHTR2CHTR3EHTR3B | |
| SCHEMBL7291352 | 0.77 | HTR2C (0.48) | NOTUMHTR2BHTR2COPRM1OPRK1 | |
| SCHEMBL15202973 | 0.76 | OPRL1 (0.42) | NOTUMHTR2BHTR2CHTR3EHTR3B | |
| SCHEMBL3597622 | 0.75 | HTR2C (0.38) | NOTUMHTR2BHTR2COPRM1OPRK1 | |
| SCHEMBL3594460 | 0.75 | NOTUM (0.40) | NOTUMHTR2BHTR2COPRM1OPRK1 | |
| SCHEMBL4418077 | 0.71 | OPRM1 (0.55) | NOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL15202972 | 0.71 | OPRM1 (0.55) | NOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL15202950 | 0.71 | OPRM1 (0.55) | NOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL1238158 | 0.70 | OPRM1 (0.62) | NOTUMOPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL2266593 | 0.69 | OPRM1 (0.60) | NOTUMOPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | NOTUM 2103/4885HTR2B 1325/4885HTR2C 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.